1. Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2. Childrens’ Hospital of Colorado, Denver, CO, USA; 3. Pediatric Heart Center, Queen Sirikit National Institute of Child Health, Rangsit University, Bangkok, Thailand; 4. Madras Medical Mission Hospital, Chennai, India; 5. Amrita Institute of Medical Sciences and Research Centre, Kochi, India; 6. National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; 7. Mater Hospital, Dublin, Ireland; 8. Our Lady’s Hospital, Crumlin, Dublin, Ireland; 9. Leeds General Infirmary, Leeds, United Kingdom; 10. Care Hospital, Hyderabad, India; 11. Fortis Escorts Heart Institute, New Delhi, India; 12. Agios Loucas Clinic, Thessaloniki, Greece; 13. Prince of Songkla University, Hat Yai, Songkla, Thailand
Aims: The aim of this study was to assess the international procedural and short-term to midterm experience with the new percutaneous Venus P-valve.
Methods and results: Retrospective data of patient characteristics, clinical and imaging follow-up of Venus P-valve implantation outside China were collected. Thirty-eight patients underwent attempted Venus P-valve implantation between October 2013 and April 2017. Thirty-seven valves were successfully implanted during 38 procedures. There was one unsuccessful attempt and there were two valve migrations, one of which required surgical repositioning. The mean follow-up was 25 months with no short-term or midterm valve failure or deterioration in performance. Frame fractures occurred in 27% of patients. The cohort demonstrated a statistically significant reduction in pulmonary regurgitation fraction and indexed right ventricular diastolic volumes at six and 12 months.
Conclusions: Implantation of the Venus P-valve has provided satisfactory short-term to midterm results with high success and low complication rates in an inherently challenging patient substrate.